NCC-149

Research use only, not for human use.

A potent and selective HDAC8 inhibitor with IC50 of 70 nM.

A potent and selective HDAC8 inhibitor with IC50 of 70 nM; displays high selectivity over major HDACs (HDAC1: IC50 38 uM, HDAC2 >100 uM, HDAC4: IC50: 44 uM,HDAC6: IC50 2.4 uM).

NCC-149 (5 μM; 3 days) remarkably reduces NeuN expression levels in P19 cells.NCC-149 (0-40 μM; 4 days) reduces embryoid body size in a dose-dependent manner.NCC-149 (5 and 20 μM; 24 h) downregulates P19 cell proliferation.NCC-149 (2.5 and 5 μM; 24 h) leads to cell growth retardation by G2/M phase arrest. Western Blot Analysis Cell Line:P19 cells Concentration:5 μM Incubation Time:3 days Result:Remarkably reduced NeuN expression levels.Cell Proliferation Assay Cell Line:P19 cells Concentration:5 and 20 μM Incubation Time:24 h Result:Downregulated cell proliferation.Cell Cycle Analysis Cell Line:P19 cells Concentration:2.5 and 5 μM Incubation Time:24 h Result:Led to a significant increase in G2/M phase cells, with a slight decrease in S phase cells.RT-PCR Cell Line:P19 cells Concentration:25 μM or 2.5 and 5 μM Incubation Time:4 days (25 μM) or 48 h (2.5 and 5 μM)Result:Did not reduce the HDAC8 expression at the mRNA level.Significantly and partially reduced cyclin B1 and cyclin A2 gene expression, respectively.

——

NCC 149 | NCC149

Cell Cycle/DNA Damage

HDAC

HDAC

——

——

1316652-41-1

326.374

C16H14N4O2S

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (383.00 mM)

O=C(NO)C1=CC=CC(C2=CN(CSC3=CC=CC=C3)N=N2)=C1

N-hydroxy-3-(1-((phenylthio)methyl)-1H-1,2,3-triazol-4-yl)benzamide

(-20℃)

With Ice Pack

≥ 2 years